written on 26.03.2014

Pfizer's targeted Xalkori outshines chemo in trial of untreated lung cancer patients


Pfizer said its targeted cancer drug Xalkori trounced chemotherapy in a trial of previously untreated patients with a particular type of lung cancer. The study showed for the first time that up-front treatment with Xalkori staves off cancer growth better than other treatments in patients whose tumors test positive for ALK-gene abnormalities.